TARIS® Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate Lexington, MA – April 2nd, 2013 – TARIS Biomedical®, a specialty pharmaceutical company developing innovative, - Deane - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2013-04-02 09:23:50 Interstitial cystitis Chronic prostatitis/chronic pelvic pain syndrome Cystitis Overactive bladder Urinary bladder disease Urination Urinary tract infection Urinary urgency Bladder cancer Medicine Health Urology		TARIS® Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate Lexington, MA – April 2nd, 2013 – TARIS Biomedical®, a specialty pharmaceutical company developing innovative, Add to Reading List Source URL: www.tarisbiomedical.com Download Document from Source Website File Size: 313,77 KB Share Document on Facebook

	Incontinence EDUCATIONAL SUPPLEMENT and Parkinson’s Disease By Debbie Guyer, MA, CCC-SLP DocID: 1poFO - View Document
	WORLD HEALTH ORGANIZATION INTERNATIONAL AGENCY FOR RESEARCH ON CANCER IARC Scientific Publications No. 147 Species Differences in Thyroid, Kidney and Urinary Bladder Carcinogenesis DocID: 1b2Gi - View Document
	http://www.reuters.com/articlePrint?articleId=US180628%2B24-Jun DocID: 19NC0 - View Document
	TARIS® Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate Lexington, MA – April 2nd, 2013 – TARIS Biomedical®, a specialty pharmaceutical company developing innovative, DocID: 19L9P - View Document
	TARIS SUCCESSFULLY COMPLETES PHASE 1 STUDY -- First Human Trial Enables Development for Several Indications -Lexington, MA – December 2, 2009 – TARIS Biomedical, a specialty pharmaceutical company pioneering the fiel DocID: 19F0k - View Document